title: Detection of BRCA1 and BRCA2 mutations in breast cancer families by a comprehensive two-stage screening procedure.
abstract: We have developed a 2-stage protocol for BRCA1 and BRCA2 mutation screening from blood spot paper. Stage 1 screening was aimed to analyze patients at highest risk for the most common disease-associated sequence variants listed in the BIC database. Accordingly, stage1 testing implied detection of 18 disease- associated BRCA1 and 9 BRCA2 mutations by adapting the 5' nuclease assay to heterozygote screening. For stage 2 screening, we applied the conformation sensitive gel electrophoresis (CSGE) method by adapting this technique to automated heteroduplex analysis of BRCA1 and BRCA2 using fragment scanning on an ABI 377 sequencing device. Of the 120 patients with a family history of breast and ovarian cancer who took part in this study so far, 45 entered stage 1 testing. Disease-associated mutations were detected in 6 patients by stage 1 testing (13%). For these patients, the final result was available within 10 days. Mutation 300T-->G was found in 2 patients. One patient with mutation 3036delACAA in BRCA2 reported only 1 sister with a multifocal bilateral breast cancer. New disease-associated mutations were detected in 2 of the 114 patients who entered the stage 2 test (1.7%). Of particular interest was 1 patient who was diagnosed with a medullary breast carcinoma at age 39 and who had no family history of breast cancer. We conclude that pre-screening by 5' nuclease assay for the mutations most frequently seen in a given population represents a relatively effective first line of analysis. Subsequent detailed analysis by fluorescence conformation sensitive gel electrophoresis (F-CSGE) and fragment sequencing is a sensitive alternative to full nucleotide sequencing.
authors.affiliation: Institute of Medical Molecular Diagnostics Ltd., Berlin, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Spitzer
authors.forename: M R
authors.initials: MR
authors.lastname: Abbaszadegan
authors.forename: F
authors.initials: F
authors.lastname: Schmidt
authors.forename: A
authors.initials: A
authors.lastname: Hauser
authors.forename: U
authors.initials: U
authors.lastname: Buwitt
authors.forename: F R
authors.initials: FR
authors.lastname: Lauter
authors.forename: K
authors.initials: K
authors.lastname: Pötschick
authors.forename: J
authors.initials: J
authors.lastname: Krocker
authors.forename: D
authors.initials: D
authors.lastname: Elling
authors.forename: R
authors.initials: R
authors.lastname: Grosse
mesh_terms: D000328:Adult; D017668:Age of Onset; D000368:Aged; D024682:BRCA2 Protein; D001943:Breast Neoplasms / Q000235:genetics*; D005091:Exons; D005190:Family; D005260:Female; D019398:Genes, BRCA1; D016147:Genes, Tumor Suppressor; D005820:Genetic Testing; D006801:Humans; D007438:Introns; D019656:Loss of Heterozygosity; D008875:Middle Aged; D009154:Mutation; D009363:Neoplasm Proteins / Q000235:genetics*; D010051:Ovarian Neoplasms / Q000235:genetics*; D017354:Point Mutation; D017384:Sequence Deletion; D014157:Transcription Factors / Q000235:genetics*
chemical_list: D024682:BRCA2 Protein; D009363:Neoplasm Proteins; D014157:Transcription Factors